Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 6/20 | 0.51 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.51 |
| ▸ | PTH1R | Q03431 | 9/20 | 0.50 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390112 | 1.00 | VIPR2 (0.51) | VIPR2VIPR1CCNA2CDK2CCNA1 | |
| SCHEMBL29391972 | 0.87 | CCNA2 (0.45) | VIPR2VIPR1CCNA2CDK2CCNA1 | |
| SCHEMBL29973246 | 0.87 | BACE1 (0.44) | PTH1R | |
| Spinigerin SCHEMBL29593748 | 0.84 | VIPR2 (0.70) | VIPR2VIPR1PTH1R | |
| SCHEMBL30512779 | 0.82 | BACE1 (0.52) | — | |
| SCHEMBL31010532 | 0.81 | BACE1 (0.48) | — | |
| SCHEMBL29711237 | 0.81 | BACE1 (0.49) | PTH1R | |
| SCHEMBL20797727 | 0.81 | SLC15A2 (0.53) | SLC15A2 | |
| SCHEMBL29466783 | 0.80 | FOLH1 (0.44) | — | |
| SCHEMBL30118983 | 0.80 | FOLH1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707410-A2 | REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS | California Institute of Technology (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA AS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20250375486-A1 | REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS | CALIFORNIA INST OF TECHN (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250281440-A1 | METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE | NUTRIQUEST, LLC | 2025-09-11 | — | — | US | disclosed |
| US-12329786-B2 | Regulate gut microbiota to treat neurodegenerative disorders | CALIFORNIA INSITUTE OF TECHNOLOGY (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025097053-A1 | DANDELION EXTRACT TO IMPROVE REPRODUCTIVE PERFORMANCE IN ANIMALS AND METHODS OF USE | NUTRIQUEST, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250057191-A1 | METHODS OF IMPROVING THE NUTRITIONAL STATUS OF IMMUNE STRESSED ANIMALS | ELANCO US INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250009892-A1 | DELIVERY SYSTEMS AND METHODS FOR REACTIVE HYDROXYL-CONTAINING COMPOUNDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2025-01-09 | — | — | US | disclosed |
| EP-4482853-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA A/S (DK) | 2025-01-01 | — | — | EP | disclosed |
| US-20220354823-A1 | SWINE MATERNAL NEONATAL PHEROMONE | TEXAS TECH UNIVERSITY SYSTEM (US) | 2022-11-10 | — | — | US | disclosed |
| US-20220338504-A1 | FEED ADDITIVE COMPOSITIONS | ELANCO US INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| EP-4030925-A1 | SWINE MATERNAL NEONATAL PHEROMONE | Texas Tech University System (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022103996-A1 | CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE | NUTRIQUEST, LLC (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220142204-A1 | CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE | NUTRIQUEST, LLC (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3986472-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3975746-A1 | THERAPEUTIC CLAY COMPOSITIONS AND METHODS OF USING | Nutriquest, LLC (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281440-A1 | METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE | PIGS, GLO1, IGFBP6 | VIPR2 3255/4885VIPR1 2556/4885CCNA2 1396/4885 |
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | ANXA11, ANXA1, ANXA4 | VIPR2 361/4885VIPR1 302/4885CCNA2 1442/4885 |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, ABCB1, NCL | VIPR2 4271/4885VIPR1 4507/4885CCNA2 1024/4885 |
| US-20220354823-A1 | SWINE MATERNAL NEONATAL PHEROMONE | PIGS, KISS1R, PGF | VIPR2 232/4885VIPR1 82/4885CCNA2 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.